Department of Hematology, Chinese PLA General Hospital, Beijing, China.
Department of Hematology-Oncology, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, Shenzhen, China.
Leuk Lymphoma. 2020 Apr;61(4):855-861. doi: 10.1080/10428194.2019.1691195. Epub 2019 Nov 22.
Chidamide, a novel histone deacetylase inhibitor, has exerted effects in T-cell tumors through various mechanisms. Seventeen patients with refractory or relapsed T-cell acute lymphoblastic lymphoma/leukemia (T-LBL/ALL) received Chidamide combined with chemotherapy as salvage treatment. Historical data was analyzed as comparison as chemotherapy group. Complete response (CR) rate and overall response rate (ORR) of Chidamide + chemotherapy group were higher than that of chemotherapy group after one course. Chidamide + chemotherapy group had a better progress-free survival (PFS) compared to chemotherapy group. No difference in overall survival (OS) was observed. Grade 3/4 nonhematological adverse events (>10%) of patients in Chidamide + chemotherapy group included febrile neutropenia (64.7%), drug-induced liver failure (17.6%), decreased fibrinogen (11.8%), sepsis (11.8%), pneumonitis (11.8%), and oral mucositis (11.8%). This study demonstrates that Chidamide included regimen may be a new treatment strategy with an acceptable safety profile for refractory or relapsed T-LBL/ALL patients but requires further investigation.
西达本胺是一种新型组蛋白去乙酰化酶抑制剂，通过多种机制在 T 细胞肿瘤中发挥作用。17 例难治性或复发性 T 细胞急性淋巴细胞白血病/淋巴瘤（T-LBL/ALL）患者接受西达本胺联合化疗作为挽救治疗。分析了历史数据作为化疗组的对照。一个疗程后，西达本胺联合化疗组的完全缓解率（CR）和总缓解率（ORR）均高于化疗组。与化疗组相比，西达本胺联合化疗组无进展生存期（PFS）更好。两组总生存期（OS）无差异。西达本胺联合化疗组患者 3/4 级非血液学不良事件（>10%）包括发热性中性粒细胞减少症（64.7%）、药物性肝衰竭（17.6%）、纤维蛋白原降低（11.8%）、败血症（11.8%）、肺炎（11.8%）和口腔粘膜炎（11.8%）。本研究表明，西达本胺联合方案可能是一种新的治疗策略，用于难治性或复发性 T-LBL/ALL 患者，具有可接受的安全性，但需要进一步研究。
